CGRP inhibitors linked to 25% lower glaucoma risk in migraine patients

Researchers tracking nearly 37,000 migraine patients have found something unexpected in their medical records: those taking a newer class of migraine-prevention drugs appear significantly less likely to develop glaucoma. The finding, published in May 2026 in Neurology, the journal of the American Academy of Neurology, suggests that drugs designed to calm the nervous system's blood vessel behavior might also protect vision—though the researchers are careful to say the evidence shows correlation, not proof of cause.

Glaucoma remains one of the world's leading causes of irreversible blindness. For decades, clinicians have noticed that migraine sufferers face elevated glaucoma risk, a connection that puzzled researchers until they realized both conditions involve the same underlying problem: blood vessels in the brain that struggle to regulate their own flow in response to changing demands. This overlap created a hypothesis worth testing. CGRP inhibitors—drugs that work by blocking a molecule involved in nerve pain and blood vessel inflammation—seemed like they might offer protection. The question was whether they actually did.

The study design was straightforward. Researchers at Brown University examined a health care database and identified 36,822 people who had just started taking CGRP inhibitors to prevent migraines, then found an equal number of patients taking other migraine-prevention medications. They followed both groups for up to three years, watching to see who developed glaucoma. The CGRP group received one of six drugs: erenumab, fremanezumab, galcanezumab, eptinezumab, atogepant, or rimegepant. The comparison group took older preventatives—blood pressure medications like candesartan or metoprolol, anticonvulsants like topiramate, or antidepressants like amitriptyline.

The raw numbers were modest but clear. Among the CGRP users, 153 people developed glaucoma—a rate of 0.42 percent. In the comparison group, 223 people developed glaucoma, or 0.61 percent. When researchers adjusted for factors known to influence glaucoma risk, such as age, how often patients experienced migraines, and whether they had high blood pressure, the difference sharpened: CGRP inhibitor users had a 25 percent lower risk.

But the story grew more specific when researchers looked closer. The protective effect appeared only in patients taking monoclonal antibody versions of CGRP inhibitors—the four drugs erenumab, fremanezumab, galcanezumab, and eptinezumab. Two other CGRP drugs in the study, atogepant and rimegepant, which work through a different mechanism called receptor antagonism, showed no glaucoma benefit. This distinction matters because it suggests the protection may depend on how the drug works, not simply on blocking CGRP itself.

Dr. Chien-Hsiang Weng, the study's lead author at Brown University, acknowledged the limitations. Researchers could not access family history of glaucoma or other detailed risk factors that might have shaped the results. The study shows association, not causation—it is possible that some unmeasured factor explains why CGRP inhibitor users developed less glaucoma, rather than the drugs themselves providing protection. Yet Weng suggested the findings open a door. Understanding why these drugs appear protective might illuminate how both migraine and glaucoma develop, potentially reshaping how doctors think about treating patients at risk for either condition.

The work now moves into a familiar phase: the need for confirmation. Larger studies, longer follow-ups, and investigation into the biological mechanisms will be required before clinicians can confidently say that CGRP inhibitors protect eye health. But for the millions of people taking these drugs for migraine, and for the millions more at risk of glaucoma, the possibility that one treatment might address both conditions is worth pursuing.